Newsroom

Sorted by: Latest

-

Il Gruppo Chiesi acquisisce KalVista Pharmaceuticals, rafforzando il portafoglio globale nelle Malattie Rare

PARMA, Italia & FRAMINGHAM, Massachusetts--(BUSINESS WIRE)--Il Gruppo Chiesi (“Chiesi”), società biofarmaceutica internazionale focalizzata sulla ricerca e azienda certificata B Corp, e KalVista Pharmaceuticals, Inc. (“KalVista”) (Nasdaq: KALV), annunciano di aver sottoscritto un accordo definitivo in base al quale Chiesi acquisirà KalVista (l’“Operazione”). L’Operazione è stata approvata all’unanimità dai Consigli di Amministrazione di entrambe le società ed è prevista chiudersi nel terzo trim...
-

Cizzle Brands Corporation Announces Major Canadian Retail Expansion with Launch of CWENCH Hydration™ at Walmart Canada and Expanded Distribution Across Loblaws and Real Canadian Superstores

TORONTO--(BUSINESS WIRE)--Cizzle Brands Corporation (Cboe Canada: CZZL) (OTCQB: CZZLF) (Frankfurt: 8YF) (“Cizzle Brands” or the “Company”), a vertically integrated sports nutrition company that is elevating the game in health and wellness, is pleased to announce a significant expansion of Canadian retail distribution for its flagship brand, CWENCH Hydration™, with two major listings. Walmart Canada — First National Listing CWENCH’s Hydration mix will be carried at 197 Walmart Canada locations n...
-

Westaim Announces Closing of Minority Stake Investment in Insignia Financial Ltd, Australia’s Leading Diversified Wealth Management Group

NEW YORK--(BUSINESS WIRE)--The Westaim Corporation (“Westaim” or the “Company”) (TSXV: WED) today announces that it has successfully closed its minority stake investment of A$35.0 million (US$25.0 million) (the “Investment”) in Insignia Financial Ltd (“Insignia”). Insignia is a world-class Australian wealth management group with over A$342 billion in funds under management and advice as of December 31, 2025. Westaim invested in the acquisition of Insignia (the “Insignia Transaction”) alongside,...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Max Buffer UCITS ETF - September 28.04.2026 MSEP.LN IE0009DRFET8 50,002.00 USD 1,374,082.12 27.481  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Rising Dividend Achievers UCITS ETF 28.04.2026 RDVY LN IE000K5F6EL4 875,002.00 USD 20,633,482.01 23.581  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust SMID Rising Dividend Achievers UCITS ETF 28.04.2026 SDVI.LN IE000YVOQ2A3 40,361.00 USD 1,155,075.93 28.619  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust SMID Rising Dividend Achievers UCITS ETF 28.04.2026 SDVY.LN IE0001R850E1 14,429,007.00 USD 363,746,715.57 25.209  ...
-

Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio

PARMA, Italy & FRAMINGHAM, Mass.--(BUSINESS WIRE)--Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, and KalVista Pharmaceuticals, Inc. (“KalVista”) (Nasdaq: KALV), today announced that the companies have entered into a definitive agreement under which Chiesi will acquire KalVista (the “Transaction”). The Transaction was unanimously approved by both Chiesi’s and KalVista’s Boards of Directors and is expected to close in Q3 2026, subject to...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Growth Strength UCITS ETF 28.04.2026 FTGS.LN IE000YZLMXT9 25,002.00 USD 562,373.73 22.493  ...
-

Medincell - UZEDY® : 63 M$ de ventes nettes au T1 2026, en hausse de 62% sur un an

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Le partenaire de Medincell (Euronext Paris : MEDCL), Teva Pharmaceuticals (NYSE et TASE : TEVA), a annoncé aujourd’hui que les ventes nettes de UZEDY aux Etats-Unis ont atteint 63 millions de dollars au premier trimestre 2026. Ce résultat représente une progression de +62% par rapport aux 39 millions de dollars enregistrés au premier trimestre 2025 et de +15 % par rapport aux ventes de 55 millions de dollars au quatrième trimestre 2025. Med...